文献速递糖尿病肥胖与代谢综合征

司美格鲁肽、替尔泊肽与袖状胃切除术治疗2型糖尿病肥胖的1年结局:回顾性队列研究

1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-06-17

该回顾性队列研究基于美国Epic Cosmos电子病历数据,比较了司美格鲁肽、替尔泊肽与袖状胃切除术在肥胖合并2型糖尿病成人中的1年减重与血糖结局。袖状胃切除术组急诊就诊及胃食管反流病和新发恶心处方率更高,但需考虑基线差异和残余混杂。

要点

  • 袖状胃切除术组急诊就诊及胃食管反流病、恶心相关处方率高于药物治疗组。
  • 解读需注意袖状胃切除术组基线BMI更高、年龄更轻、HbA1c更低及残余混杂。

核心结论

  • 在指数日期后1年,袖状胃切除术达到体重和血糖联合目标的概率最高,其次为替尔泊肽,司美格鲁肽最低。

主要发现

  • 袖状胃切除术组1年内急诊就诊比司美格鲁肽或替尔泊肽组更频繁。
  • 胃食管反流病和新发恶心处方在所有治疗组均有发生,但袖状胃切除术组绝对发生率更高。

关键数值与推荐

  • 预设安全性结局包括指数日期后1年内急诊就诊及胃食管反流病或恶心新处方。

临床怎么用

  • 对于肥胖合并2型糖尿病成人,袖状胃切除术在1年联合减重和血糖达标方面概率最高,但需权衡急诊就诊及胃肠道不良反应风险。
  • 替尔泊肽在药物治疗中达标概率高于司美格鲁肽,可作为强化治疗选择之一。
  • 临床决策应结合患者基线特征(如BMI、年龄、HbA1c)及偏好个体化选择。

局限性

  • 解读需考虑基线差异:袖状胃切除术组BMI更高、年龄更轻、基线HbA1c更低。
  • 存在残余混杂。
  • 安全性评估范围有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Type 2 diabetes and obesity are prevalent, inter-related conditions for which treatment options have expanded substantially, yet direct real-world comparisons of modern pharmacological and surgical interventions remain scarce. We aimed to compare 1-year weight loss, glycaemic outcomes, and selected safety outcomes associated with semaglutide, tirzepatide, and sleeve gastrectomy among adults with obesity and type 2 diabetes in real-world clinical practice. METHODS: We conducted a retrospective cohort study using Epic Cosmos, a de-identified electronic health record dataset from 1633 hospitals and 37 900 clinics across 280 health systems in the USA. Adults with a BMI of at least 35 kg/m2 and HbA1c above 6·4% who initiated at least 12 months of therapy with semaglutide or tirzepatide and attaining maintenance doses, or who underwent sleeve gastrectomy, were eligible for inclusion. The primary outcome was attainment of at least 20% bodyweight loss and HbA1c below 5·7% at 1 year after the index date. Multivariable logistic regression estimated adjusted probabilities and relative risks, adjusting for age, sex, race, baseline HbA1c, BMI, Charlson Comorbidity Index, Social Vulnerability Index (SVI 2020), and baseline medication burden for diabetes, lipids, and hypertension. Prespecified safety outcomes included emergency department visits and new prescriptions for gastro-oesophageal reflux disease or nausea within 1 year of the index date. The primary composite outcome was analysed among patients with both follow-up weight and HbA1c available in the 9-month to 15-month window. Emergency department visits were analysed in the final analysis cohort (ie, patients meeting all inclusion and exclusion criteria and with available baseline and 9-month to 15-month weight and HbA1c measurements) and medication-based safety outcomes were analysed descriptively using outcome-specific available data denominators without imputation. FINDINGS: A total of 468 712 patients with at least 365 consecutive days of semaglutide or tirzepatide prescriptions and 238 028 patients undergoing sleeve gastrectomy were identified in Epic Cosmos. After applying prespecified inclusion and exclusion criteria, 45 649 patients met inclusion criteria; after exclusion of 556 patients with missing Charlson Comorbidity Index data, 45 093 were included in the primary outcome analysis: 33 482 (74·3%) treated with semaglutide, 4178 (9·3%) treated with tirzepatide, and 7433 (16·5%) who underwent sleeve gastrectomy. The adjusted probability of attaining the primary composite outcome of at least 20% bodyweight loss and HbA1c below 5·7% at 1 year was 3·0% (95% CI 2·8-3·2) for semaglutide, 13·2% (12·2-14·3) for tirzepatide, and 24·0% (22·9-25·1) for sleeve gastrectomy. Emergency department visits within 1 year were more frequent after sleeve gastrectomy than after semaglutide or tirzepatide. New prescriptions for gastro-oesophageal reflux disease and nausea occurred in all treatment groups but varied in frequency, with higher absolute rates observed after sleeve gastrectomy. INTERPRETATION: At 1 year after the index date, sleeve gastrectomy was associated with the highest probability of attaining combined weight and glycaemic targets, followed by tirzepatide and semaglutide. Interpretation should consider baseline differences-including higher BMI, younger age, and lower baseline HbA1c in the sleeve gastrectomy group-as well as residual confounding and the limited scope of safety assessment. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Leslie DB, Steffen BT, Wise E, et al. 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study. Lancet Diabetes Endocrinol. 2026. PMID: 42309121. doi:10.1016/S2213-8587(26)00030-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。